Aleve

Aleve. It is a brand name for the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium, a medication widely used for its analgesic, anti-inflammatory, and antipyretic properties. Marketed by Bayer in the United States and by other companies globally, it is available over-the-counter for the temporary relief of minor aches and pains. Its long duration of action, typically providing relief for 8 to 12 hours, distinguishes it from some other common NSAIDs like ibuprofen.

Medical uses

Aleve is indicated for the treatment of various conditions involving pain and inflammation. Common uses include the relief of headache, muscle aches, tendinitis, dental pain, menstrual cramps, and the arthritis associated with osteoarthritis and rheumatoid arthritis. It is also effective in reducing fever and managing the pain of gout attacks. For more severe or chronic conditions, such as ankylosing spondylitis or juvenile arthritis, a prescription-strength version may be utilized under the guidance of a healthcare professional like those at the American College of Rheumatology.

Adverse effects

As with all NSAIDs, use carries a risk of adverse effects, particularly with long-term or high-dose administration. Common side effects involve the gastrointestinal tract, including dyspepsia, heartburn, and nausea. More serious risks include peptic ulcer disease, gastrointestinal bleeding, and perforation, especially in elderly patients or those taking concomitant medications like warfarin or corticosteroids. Cardiovascular risks, such as an increased chance of myocardial infarction or stroke, are associated with NSAID use, as noted by regulatory bodies like the U.S. Food and Drug Administration (FDA). Other potential effects include renal impairment, hepatotoxicity, and rare but severe skin reactions like Stevens–Johnson syndrome.

Pharmacology

Naproxen, the active moiety, works by non-selectively inhibiting the cyclooxygenase (COX) enzymes, COX-1 and COX-2. This inhibition blocks the conversion of arachidonic acid into prostaglandins and thromboxane, which are mediators of pain, inflammation, and fever. Its pharmacokinetic profile includes high oral bioavailability and extensive binding to plasma proteins, primarily albumin. Metabolism occurs in the liver via the cytochrome P450 system, specifically the CYP1A2 and CYP2C9 isoenzymes, and excretion is primarily renal. Its relatively long half-life allows for less frequent dosing compared to agents like aspirin.

History

Naproxen was first synthesized by the Italian pharmaceutical company Syntex in the late 1960s, with researchers like John Robert Vane contributing to the understanding of NSAID mechanisms. It received approval from the FDA for prescription use in the United States in 1976. The over-the-counter version, branded as Aleve, was launched in the United States in 1994 by Procter & Gamble through a joint venture with Roche. The brand ownership later transferred to Bayer after its acquisition of the Merck Consumer Care division, solidifying its place in the global analgesic market alongside competitors like Johnson & Johnson's Tylenol.

Society and culture

Aleve occupies a significant position in the consumer healthcare market, with extensive advertising campaigns often emphasizing its long-lasting relief. It is frequently compared to other OTC analgesics like Advil (ibuprofen) and Tylenol (acetaminophen) in both media and clinical studies. Regulatory decisions by the European Medicines Agency and the FDA have shaped its labeling, particularly regarding cardiovascular and gastrointestinal risks. The drug is also listed on the World Health Organization's Model List of Essential Medicines, highlighting its global importance. Cultural references occasionally appear in contexts discussing sports medicine or everyday pain management.

Category:Nonsteroidal anti-inflammatory drugs Category:Bayer brands